| Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label … SP Eholie, DK Ekouevi, C Chazallon, C Charpentier, E Messou, Z Diallo, ... The Lancet HIV 11 (6), e380-e388, 2024 | 2 | 2024 |
| Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France R Seng, P Frange, A Faye, C Dollfus, J le Chenadec, F Boufassa, A Essat, ... The Lancet Regional Health–Europe 40, 2024 | | 2024 |
| Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection A Bachelard, Q Le Hingrat, VM Ferré, M Lê, G Peytavin, F Damond, ... Clinical Infectious Diseases 78 (4), 1005-1010, 2024 | | 2024 |
| Favorable outcome without corticosteroids during post-artesunate delayed hemolysis with positive direct antiglobulin test in severe imported Plasmodium falciparum malaria, France O Paccoud, X Chamillard, E Kendjo, I Vinatier, L Surgers, D Magne, ... International Journal of Infectious Diseases 137, 144-148, 2023 | 1 | 2023 |
| Within-Host Dynamics and Duration of Colonization of Travel-Acquired Multidrug-Resistant Enterobacterales in Untreated Individuals O Cotto, L Armand-Lefèvre, S Matheron, E Ruppé, F Blanquart Clinical Infectious Diseases 77 (6), 934-936, 2023 | | 2023 |
| Cytokine profiles in adults with imported malaria C de Roquetaillade, C Laouenan, JP Mira, C Roy, M Thuong, É Azoulay, ... Scientific Reports 13 (1), 10347, 2023 | 1 | 2023 |
| L'Anguillulose autochtone en métropole, qui est à risque? B Heid-Picard, J Ghosn, M Parisey, S Hamane, S Bretagne, J Molina, ... Médecine et Maladies Infectieuses Formation 2 (2), S121-S122, 2023 | | 2023 |
| Within-host density and duration of colonization of multidrug-resistant Enterobacterales acquired during travel to the tropics O Cotto, L Armand-Lefèvre, S Matheron, E Ruppé, F Blanquart bioRxiv, 2023.03. 03.530937, 2023 | | 2023 |
| Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort S Grabar, V Potard, L Piroth, S Abgrall, L Bernard, C Allavena, F Caby, ... Journal of Antimicrobial Chemotherapy 78 (3), 757-768, 2023 | 10 | 2023 |
| Late dihydroartemisinin-piperaquine treatment failure of P. falciparum malaria attack related to insufficient dosing in an obese patient M Parisey, S Houze, J Bailly, N Taudon, K Jaffal, N Argy, C Rouzaud, ... IDCases 33, e01847, 2023 | | 2023 |
| Acquisition of Enterobacterales carrying the colistin resistance gene mcr following travel to the tropics E Rondinaud, O Clermont, M Petitjean, E Ruppé, M Esposito-Farèse, ... Journal of Travel Medicine 30 (1), taac141, 2023 | 2 | 2023 |
| Vaccinations. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Cytokine profiles in adults with imported malaria: insights from the PALUREA cohort study C de Roquetaillade, C Laouenan, JP Mira, C Roy, M Thuong, É Azoulay, ... bioRxiv, 2022.11. 23.517616, 2022 | | 2022 |
| Business risks. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Risks related to arthropods and personal anti-vector protection (PPAV). S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Traveler's diarrhoea and other risks related to faecal peril. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Imported diseases: preventing the risk of dissemination of infectious diseases on return from travel-Pharmacovigilance system for reporting adverse effects. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Risks related to certain behaviours or situations. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Transport risks. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
| Person-specific precautions. S Matheron, E Nicand, C Rapp, C Chidiac | | 2022 |
